Provided by Tiger Trade Technology Pte. Ltd.

CASI Pharmaceuticals

0.2075
0.0000
Volume:- -
Turnover:3.06M
Market Cap:4.26M
PE:-0.07
High:0.2075
Open:0.2075
Low:0.2075
Close:0.2075
52wk High:3.09
52wk Low:0.2075
Shares:20.55M
Float Shares:9.33M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9845
EPS(LYR):-2.5591
ROE:-1094.50%
ROA:-61.80%
PB:-0.15
PE(LYR):-0.08

Loading ...

Wei-Wu He - Will Not Consider Any Pipe Financing Transaction as an Alternative

THOMSON REUTERS
·
Jan 09

Wei-Wu He - Intends to Finance the Transactions Contemplated by Proposal Through Combination of Debt and Equity

THOMSON REUTERS
·
Jan 09

CASI Pharmaceuticals Faces Nasdaq Delisting Risk Pending Compliance with Listing Standards

Reuters
·
Dec 24, 2025

Sprinkles (HK) Charity Foundation Donates to The Education University of Hong Kong to Promote "Harmony between Humanity and Nature Sustainable Education" Project

prnewswire
·
Dec 23, 2025

CASI Academy Launches Sustainable Investing Program for Hong Kong's MPF Industry

prnewswire
·
Dec 18, 2025

CASI Pharmaceuticals Inc - Investment to Fund Phase 1 Study in Renal Allograft Antibody-Mediated Rejection (Amr) in China

THOMSON REUTERS
·
Dec 11, 2025

CASI Pharmaceuticals Inc - Announces up to $20 Mln Convertible Note Financing

THOMSON REUTERS
·
Dec 11, 2025

CASI Pharmaceuticals Reports Positive Phase 1 Results for CID-103 in Immune Thrombocytopenia

Reuters
·
Dec 08, 2025

CASI Pharmaceuticals Appoints James Huang as Non-Executive Chairman

Reuters
·
Nov 19, 2025

CASI Pharmaceuticals Reports Q3 2025 Results Amid Nasdaq Delisting Appeal

TIPRANKS
·
Nov 15, 2025

CASI Pharmaceuticals Q3 EPS $(0.67) Misses $(0.51) Estimate, Sales $3.075M Down From $7.793M YoY

Benzinga
·
Nov 15, 2025

CASI Pharmaceuticals Reports Third Quarter Revenue of $3.1 Million and Net Loss of $10.9 Million

Reuters
·
Nov 15, 2025

North American Morning Briefing: Futures Decline as Investor Caution Rises

Dow Jones
·
Nov 13, 2025

PRI-CASI Sustainability Forum for COP30 concluded in Brazil

prnewswire
·
Nov 12, 2025

CASI Pharmaceuticals Inc- Receives & Appeals Delisting Determination From Nasdaq

THOMSON REUTERS
·
Nov 11, 2025

CASI Pharmaceuticals Appeals Nasdaq Delisting Determination

Reuters
·
Nov 11, 2025

CASI Pharmaceuticals Joins Guggenheim Healthcare Innovation Conference

Reuters
·
Nov 04, 2025

CASI Pharmaceuticals to Present Phase 1 CID-103 ITP Trial Results at ASH 2025

Reuters
·
Nov 03, 2025

Little Excitement Around CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues As Shares Take 43% Pounding

Simply Wall St.
·
Sep 30, 2025

Casi Pharmaceuticals appoints James Hunag to board of directors

TIPRANKS
·
Sep 26, 2025